Lemtrada
Use of Genzyme’s MS drug Lemtrada restricted under ongoing EMA safety review
April 16, 2019Manufacturing and Production, Sales and Marketing EMA, Genzyme, Lemtrada, multiple sclerosis, pharma
The EMA has launched a review into Genzyme’s multiple sclerosis drug Lemtrada (alemtuzumab) after reports emerged of treatment-related safety issues …
Lemtrada shows clinical efficacy in multiple sclerosis in 10-year follow-up data
April 20, 2016Research and Development, Sales and Marketing Lemtrada, Sanofi, alemtuzumab, multiple sclerosis, sanofi genzyme
Sanofi Genzyme has presented 10-year follow-up data on Lemtrada (alemtuzumab) which points to its efficacy in patients with relapsing-remitting multiple …
Genzyme’s Lemtrada shows five-year efficacy in extended trials
October 8, 2015Research and Development Genzyme, Lemtrada, MS, RRMS, alemtuzumab, multiple sclerosis, relapsing-remitting multiple sclerosis
Sanofi’s subsidiary Genzyme has achieved positive data from an extension study of Lemtrada in patients with relapsing remitting multiple sclerosis …
FDA green lights Lemtrada for MS
November 17, 2014Sales and Marketing FDA, Genzyme, Lemtrada, MS, Sanofi, rems, tecfidera
The US FDA has approved Sanofi’s Lemtrada for multiple sclerosis, almost a year after rejecting the drug on concerns about …
Shortlist announced for best new pharma product
June 24, 2014Research and Development, Sales and Marketing Esbriet, InterMune, Lemtrada, Orphan, dificlir, innovative, pif, prix galion, selincro
Treatments for idiopathic pulmonary fibrosis, hepatic encephalopathy and meningococcal infection are among 14 new medicines shortlisted for the UK Prix …
Lemtrada resubmitted to FDA
June 2, 2014Sales and Marketing FDA, Lemtrada, MS, Sanofi
Sanofi has resubmitted its application for Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis (MS) to the …
NICE wants more Lemtrada data
December 6, 2013Sales and Marketing Lemtrada, MS, NICE, Sanofi
NICE has said there are ‘still questions to be answered’ over Sanofi’s submission of its multiple sclerosis drug Lemtrada and …
‘Fatal’ safety concerns throw doubt on Lemtrada
November 11, 2013Research and Development, Sales and Marketing FDA, Genzyme, Lemtrada, MS, Sanofi
An FDA committee has dashed hopes of an approval for Sanofi’s multiple sclerosis drug after saying its benefits may not …
Sanofi’s Lemtrada given European go ahead
September 18, 2013Research and Development, Sales and Marketing Aubagio, Lemtrada, MS, Sanofi, gilenya
Sanofi’s Lemtrada nears EU approval
July 1, 2013Sales and Marketing CHMP, Genzyme, Lemtrada, Sanofi
Sanofi’s multiple sclerosis drug Lemtrada has received a positive recommendation from the CHMP, meaning a European approval is likely just …
Sanofi criticised for multiple sclerosis manoeuvres
November 2, 2012Sales and Marketing Cancer, Lemtrada, MS, Sanofi
Sanofi is facing a backlash as it prepares its new MS treatment for the market. Lemtrada (alemtuzumab) has produced very …
Genzyme ‘confident’ of FDA nod for MS drug
August 29, 2012Sales and Marketing Genzyme, Lemtrada, MS, multiple sclerosis
Genzyme insists it is on course to resubmit an existing oncology drug for the treatment of relapsing multiple sclerosis (RMS), …
Sanofi submits key MS pill for approval
June 12, 2012Research and Development, Sales and Marketing Bayer, EMA, FDA, Genzyme, Lemtrada, MS, Sanofi
Sanofi has submitted its multiple sclerosis pill Lemtrada for regulatory reviews in the US and Europe. Lemtrada (alemtuzumab), originally developed …
Sanofi’s Lemtrada beats Rebif in new study
November 14, 2011Research and Development, Sales and Marketing Lemtrada, Rebif, Sanofi
Lemtrada has beaten Merck Serono’s multiple sclerosis treatment Rebif in a new head-to-head trial, paving the way for regulatory submission …
Latest content
FibroFind appoints Lee Borthwick as CEO
